Agentic discovery
PaiX Navigator Platform for global data insights.
PaiX Navigator is the flagship platform of the PaiX ecosystem. Ask a question in plain language, build cohorts across AI-ready public and proprietary datasets from 60+ countries, and take the insight or license the data, all in one place.
PATHOLOGY
RADIOLOGY
GENOMICS
LABS & CLINICAL
PATIENT RECORD
NAME
DOB
MRN
DIAGNOSISKEPT
MODALITIESLINKED
PAIX EDGE
INGESTION & NORMALIZATION
PAIX ATLAS
LONGITUDINAL & HARMONISATION
PAIX NAVIGATOR
FLAGSHIP PLATFORM
Illustrative demo · data shown is for illustrative purposes only
The flagship · PaiX Navigator
From query to AI-ready dataset.
From question to defensible answer in days, not quarters. Ask in plain language, see where every cohort came from, and take the insight or the data.
Agentic discovery
Agents find the cohort and explain where every record came from.
Multi-modal
data
data
Every modality, one standard.
Multi-modal
data
data
Pathology and clinical live now. Radiology, omics and labs next.
Disease
agnosticOncology first.
agnostic
Oncology first.
More to come.
Disease
agnostic
agnostic
63 cancer types in the datalake. Cardiology, neurology and rare next.
Population insights
See the whole population.
Population insights
Biomarker prevalence and real-world outcomes from AI-ready public and proprietary datasets across 60+ countries.
AI-ready, licensed
License AI-ready datasets.
AI-ready, licensed
Labelled, versioned, compliant. Drops straight into your pipeline.
Pick your path
Four ways to work with PaiX Navigator.
Query for insights without moving the data, license the cohort and bring it in-house, tell us what is missing and we will go acquire it, or put your own archive to work as a data partner. Most teams use more than one.
Data insights
Ask. Get answers.
Query the deeper dataset behind every cohort. Answers leave the platform, the data never does.
YOU GETAnswers & briefs
DATA MOVESNever
BEST FORMarket sizing · RWE
Data licensing
License it. Bring it in-house.
Annual license with a buyout option. Audit-ready, with consent and provenance attached.
YOU GETThe cohort, in-house
TERMSAnnual · buyout option
BEST FORTraining & validation
Data acquisition
Missing? We acquire it.
Scope the cohort with the agent and we source it from hospital partners across 60+ countries, delivered as AI-ready public and proprietary datasets.
YOU GETData built to order
SOURCED FROM60+ country network
BEST FORRare & missing cohorts
Data partnership
Become our data partner.
Host ethically approved, GDPR-compliant data on-site: keep full control, share revenue when cohorts are licensed.
YOU GETRevenue share
DATA MOVESStays on your site
BEST FORHealth data owners
Licensable data
A glimpse into our licensable data.
Two examples from a growing catalogue of licensable cohorts in the PaiX datalake. Every cohort ships harmonised, versioned and audit-ready, with consent and provenance attached. Ask us for the full list.
Multi-cancer pathologyPAI012
Curated multi-cancer WSI + pathology cohort
2,606patients with digitised WSIs paired with full clinical pathology reports
912malignant patients with fully paired H&E + IHC and complete annotation
Total WSIs24,641 (8,950 H&E, 15,511 IHC)
AnnotationDiagnosis, tumour grade, specimen type, IHC results
Deepest indicationBreast: ER, PR, HER2 and Ki67 across ~400 patients
TermsAnnual license · buyout option
Global diagnostic consultationPAI034
Global diagnostic consultation cohort
~72,000real-world consultation cases submitted by clinicians worldwide
~927,000processed images, QC-passed subset
Slide mix~76% pathology (H&E, cytology, IHC), ~2% radiology
Structured IHC~4,700 cases across ~200 markers
Organ coveragePan-organ; ~35% of classified cases malignant
TermsAnnual license · buyout option
Across the drug R&D journey
From first biomarker to market: PaiX Navigator at every step.
Every stage runs on evidence. PaiX Navigator delivers harmonised, global, AI-ready data at each step.
Current practice
With PaiX
Biomarker discovery
Current practiceValidated where cohorts existDiscovery cohorts skew to a few populations. Generalisability is assumed rather than measured.
With PaiXValidated across geographiesBiomarker prevalence and disease biology variation, globally.
Clinical trial design
Current practiceFeasibility from partial evidenceLiterature, registries and established site networks. Reliable where the data reaches, thin beyond it.
With PaiXDesigned on real cohortsSizing, sites and stratification from AI-ready public and proprietary datasets across 60+ countries.
Off-target & safety
Current practicePowered for the overall populationSubgroup specific signals are too rare to surface until post market surveillance.
With PaiXSeen before launchSubgroup-stratified signal across regions and modalities.
Patient stratification PHASE 3 TO 4
Current practiceSubgroups underpoweredDifferences are reported as inconclusive rather than quantified.
With PaiXSubgroups quantifiedBias-stratified performance and outcomes in Phase 3–4.
Market entry
Current practicePrevalence extrapolatedModelled from reference markets and adjusted. Confident in established geographies, uncertain outside them.
With PaiXMeasured by geographyReal prevalence for market sizing and competitive intel.
PaiX Navigator · Book a demo
Let's talk about PaiX in your work.
Book a demo or send us a message about data insights, acquisition, licensing or partnerships. We'll show you how PaiX Navigator integrates into your pipeline and what it can answer for you.